Cargando…

ERRATUM: A unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid leukemia, following relapse 18 months post allogeneic stem cell transplant

Detalles Bibliográficos
Autores principales:	Horgan, Claire, Kanellopoulos, Alexandros, Paneesha, Shankara, Kishore, Bhuvan, Lovell, Richard, Nikolousis, Emmanouil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications, Pavia, Italy 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686852/ https://www.ncbi.nlm.nih.gov/pubmed/33282167 http://dx.doi.org/10.4081/hr.2020.8995

Ejemplares similares

A unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid leukemia, following relapse 18 months post allogeneic stem cell transplant
por: Horgan, Claire, et al.
Publicado: (2019)

Reduced Intensity Allogeneic Stem Cell Transplant for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
por: Lokare, Anand, et al.
Publicado: (2014)

Autoimmune Cytopenias Developing Late Post Alemtuzumab-Based Allogeneic Stem Cell Transplantation: Presentation of Short Case Series from a Transplant Center
por: Lloyd, Rebecca, et al.
Publicado: (2020)

First case of near haploid philadelphia negative B-Cell acute lymphoblastic leukaemia relapsing as acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation
por: Horgan, Claire, et al.
Publicado: (2020)

Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy Alterations
por: Kaparou, Maria, et al.
Publicado: (2021)

Clonal expansion of CD8(+) T cells reflects graft-versus-leukemia activity and precedes durable remission following DLI
por: Schultze-Florey, Christian R., et al.
Publicado: (2021)

Therapeutic Strategies for DLI: How Should DLI Be Treated?
por: Homma, Sakae
Publicado: (2017)

A Retrospective Comparison of DLI and gDLI for Post-Transplant Treatment
por: Lamure, Sylvain, et al.
Publicado: (2020)

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
por: Döhner, Hartmut, et al.
Publicado: (2022)

DLI Induced by Herbal Medicine: What Are the Characteristics of DLI due to Herbal Medicines?
por: Abe, Mitsuhiro, et al.
Publicado: (2017)

Durable remission of acute myeloid leukemia in an elderly patient following a limited course of azacitidine and venetoclax
por: Ehsan, Hamid, et al.
Publicado: (2022)

Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS
por: Gregory, Gareth P., et al.
Publicado: (2019)

Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation
por: Niscola, Pasquale, et al.
Publicado: (2019)

Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients
por: Greiner, Jochen, et al.
Publicado: (2019)

Comparison of the effect of DLI according to cell sources in relapsed AML after allogeneic stem cell transplantation
por: Park, Woochan, et al.
Publicado: (2023)

ASD Is Not DLI: Individuals With Autism and Individuals With Syntactic DLI Show Similar Performance Level in Syntactic Tasks, but Different Error Patterns
por: Sukenik, Nufar, et al.
Publicado: (2018)

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3(mut+) AML ineligible for intensive chemotherapy
por: Wang, Eunice S., et al.
Publicado: (2022)

Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis
por: Yang, Minglei, et al.
Publicado: (2018)

Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia
por: Craddock, Charles, et al.
Publicado: (2019)

Azacitidine as Salvage Therapy for Acute Myeloid Leukemia in a Severely Ill Patient
por: Powers, Harry Ross, et al.
Publicado: (2014)

Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3‐internal tandem duplication AML: The JALSG AML209‐FLT3‐SCT study
por: Kawashima, Naomi, et al.
Publicado: (2020)

Venetoclax-azacitidine as salvage therapy for relapsed mixed phenotype acute leukemia after a second allogeneic hematopoietic stem cell transplantation: a case report
por: Mekni, Sabrine, et al.
Publicado: (2023)

Salvage Therapy Using Azacitidine for Relapsed Primary Myelofibrosis after Cord Blood Transplantation
por: Sumi, Masahiko, et al.
Publicado: (2020)

Gilteritinib Combined with Azacitidine as Salvage Therapy for B/Myeloid Mixed Phenotype Acute Leukemia
por: Horvat, Nathan P, et al.
Publicado: (2022)

The postpartum depression literacy scale (PoDLiS): development and psychometric properties
por: Mirsalimi, Fatemeh, et al.
Publicado: (2020)

SPIN(DLY)-OFF: A tale of conformational change to control DYNEIN
por: Barbosa, João, et al.
Publicado: (2022)

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
por: Othman, Jad, et al.
Publicado: (2023)

S137: IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN FIRST COMPLETE REMISSION PLUS FLT3 INHIBITION WITH QUIZARTINIB IN ACUTE MYELOID LEUKEMIA WITH FLT3-ITD: RESULTS FROM QUANTUM-FIRST
por: Schlenk, Richard, et al.
Publicado: (2023)

Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
por: Konopleva, Marina, et al.
Publicado: (2022)

Durable response of therapy-related MDS/AML with concomitant Waldenström’s macroglobulinemia treated with venetoclax and azacitidine
por: Hirano, Mitsuhito, et al.
Publicado: (2022)

Minor Antigen Vaccine-Sensitized DLI: In Vitro Responses Do Not Predict In Vivo Effects
por: Rosinski, Steven Lawrence, et al.
Publicado: (2016)

Complete Remission Obtained with Azacitidine in a Patient with Concomitant Therapy Related Myeloid Neoplasm and Pulmonary Mucormycosis
por: Capria, S., et al.
Publicado: (2013)

Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations
por: Garz, Anne-Kathrin, et al.
Publicado: (2017)

Two cases of aspergillus endocarditis in non neutropenic children on chemotherapy for acute lymphoblastic leukaemia
por: Nikolousis, Emmanouil, et al.
Publicado: (2011)

Durable Leukemic Remission and Autologous Marrow Recovery with Random Chromosomal Abnormalities after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia
por: Nishikii, Hidekazu, et al.
Publicado: (2019)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

A Transcriptome Analysis Identifies Biological Pathways and Candidate Genes for Feed Efficiency in DLY Pigs
por: Wang, Xingwang, et al.
Publicado: (2019)

DLI-IT: a deep learning approach to drug label identification through image and text embedding
por: Liu, Xiangwen, et al.
Publicado: (2020)

Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML
por: Vachhani, Pankit, et al.
Publicado: (2016)

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
por: Yuan, Linyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6jm4n5ij4i7ea36levf6gtpeha